May 07, 2019
Regeneron Reports First Quarter 2019 Financial and Operating Results
Apr 15, 2019
Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
Apr 08, 2019
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
Mar 11, 2019
New Genetic Data from Regeneron and GSK on 50,000 UK Biobank Participants Made Available to Global Health Research Community
Mar 08, 2019
FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps
Mar 01, 2019
CHMP Recommends Approval of Dupixent® (dupilumab) for Asthma Indication
Feb 11, 2019
Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price
Feb 06, 2019
Regeneron Reports Fourth Quarter and Full Year 2018 Financial and Operating Results
Jan 07, 2019
Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference
Jan 07, 2019
Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs
Dec 01, 2018
Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Nov 06, 2018
Regeneron Reports Third Quarter 2018 Financial and Operating Results
Nov 06, 2018
FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis
Oct 27, 2018
Two-year data for Novartis brolucizumab reaffirm superiority versus aflibercept in reducing retinal fluid in patients with nAMD
Oct 25, 2018
EYLEA® (aflibercept) Injection Improves Diabetic Retinopathy and Reduces Vision-Threatening Complications in Phase 3 Trial
Oct 19, 2018
FDA Approves Asthma Indication for Dupixent® (dupilumab)
Oct 08, 2018
Libtayo® (cemiplimab-rwlc) Data at ESMO 2018 Congress Provide New Insights in Six Tumor Types Under Investigation
Sep 28, 2018
FDA Approves Libtayo® (cemiplimab-rwlc) as First and Only Treatment for Advanced Cutaneous Squamous Cell Carcinoma
Sep 24, 2018
Oculis Appoints World-renowned Ophthalmology Specialist
Sep 13, 2018
FDA to Review EYLEA (aflibercept) Injection for the Treatment of Diabetic Retinopathy